Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A **small-molecule combination procedural injection kit** containing **methylprednisolone acetate**, **lidocaine hydrochloride**, **povidone-iodine**, and **isopropyl alcohol**. The therapeutic component is methylprednisolone acetate, a depot synthetic glucocorticoid corticosteroid that activates the **glucocorticoid receptor** to suppress inflammatory and immune signaling; lidocaine hydrochloride is included as a local anesthetic to reduce injection-site pain, while povidone-iodine and isopropyl alcohol are topical antiseptics used for skin preparation before administration. In practice, this type of kit is used to facilitate intramuscular, intra-articular, soft-tissue, or intralesional corticosteroid injection procedures across multiple inflammatory and immune-mediated conditions. The underlying marketed corticosteroid component is associated with Pfizer through the Depo-Medrol methylprednisolone acetate product lineage, while the kit itself appears to be a combination convenience product rather than a distinct new molecular entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isopropyl alcohol + lidocaine hydrochloride + methylprednisolone acetate + povidone-iodine.